Merck Finalizes Acquisition of Terns Pharmaceuticals
TERN has more than doubled off its 52-week low of $2.655.
Summary
Merck has completed its acquisition of Terns Pharmaceuticals, Inc. This finalizes a strategic transaction that was previously signaled by the expiration of the Hart-Scott-Rodino Act waiting period on April 24th. Furthermore, Merck's Q1 10-Q, filed on May 4th, already disclosed an expected $5.8 billion charge related to the Terns acquisition, indicating the financial impact was largely anticipated. For Terns Pharmaceuticals (TERN), this event is highly significant as it marks the definitive end of its independent public trading, providing liquidity to its shareholders. For Merck (MRK), it confirms the closing of a deal whose financial implications were already largely accounted for in its recent earnings and guidance.
At the time of this announcement, TERN was trading at $52.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $2.66 to $53.19. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.